Search
for
Sort by
Research 331–360 of 1000+
- Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease
- Functional characterization and unraveling the structural determinants of novel steroid hydroxylase CYP154C7 from Streptomyces sp. PAMC26508
- Identification of Cashmere and Other Animal Hair Fibers in Textiles by MALDI-TOF Mass Spectrometry
- Scabiosis, Otitis Externa, With Toxocariosis and Ancylostomiasis In Local Cat
- Le mélanome malin bilatéral de l'uvée
- From Russia with Love
- Improved Transgender Care in the ED
- The Case Files
- The Case Files
- The Case Files
- The Case Files
- Iconography : Future Horizons in Hair Restoration
- After the Match
- Screened & Examined
- Symptoms: Pruritic Skin Lesions
- Painful, Unexplained Peripheral Neuropathy? Think Thallium Toxicity
- Community-Acquired MRSA
- Diagnosis
- Hair Drug Testing Routine in Many Clinical and Forensic Applications
- Alterations of plasma antioxidants and mitochondrial DNA mutation in hair follicles of smokers
- The application of platelet-rich plasma in the treatment of androgenic alopecia
- Evolutionary Medicine: Perspectives on Human Development and Health Consequences in a Changing Environment. The 7th International Conference
- Obtenção e caracterização do óleo de sementes de girassol enriquecido com compostos ativos de grãos de café verde defeituosos
- ESTUDO DE PRÉ-FORMULAÇÃO DE SHAMPOO PARA TRATAMENTO DA ALOPECIA ANDROGENÉTICA CONTENDO CAFEÍNA COMO ATIVO
- Associação do Microagulhamento e Fatores de Crescimento para Estímulo do Crescimento das Sobrancelhas
- UTILIZAÇÃO DE ISOTRETINOÍNA ORAL NO TRATAMENTO DA ALOPECIA FIBROSANTE FRONTAL: SÉRIE DE CASOS
- UTILIZAÇÃO DE ISOTRETINOÍNA ORAL NO TRATAMENTO DA ALOPECIA FIBROSANTE FRONTAL: SÉRIE DE CASOS
- CARACTERÍSTICAS CLÍNICAS DO EFLÚVIO TELÓGENO INDUZIDO PELA INFECÇÃO DE COVID-19: REVISÃO INTEGRATIVA
- APLICAÇÃO DE PLANEJAMENTO DE EXPERIMENTOS (DoE) PARA OTIMIZAÇÃO DE MÉTODO ANALÍTICO PARA QUANTIFICAÇÃO DE MINOXIDIL POR CLAE
- Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.